Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
Launched by UNIVERSITY OF COLORADO, DENVER · Nov 10, 2023
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how losing weight can affect certain tissues in the body, specifically intermuscular adipose tissue (IMAT), in people who are obese. The researchers want to understand how inflammatory substances released by this tissue can lead to muscle problems like insulin resistance and inflammation. By examining these substances before and after a 12-week weight loss program, they hope to find out if weight loss helps reduce these harmful molecules and improves muscle health.
To join the study, participants should generally be healthy adults between the ages of 18 and 70 with a body mass index (BMI) between 30 and 40, and they should not exercise more than one hour a week. Unfortunately, individuals with diabetes, certain thyroid or lung diseases, and some other health conditions cannot participate. Those who take specific medications or are currently pregnant or breastfeeding are also excluded. Participants can expect to go through several tests, including body composition measurements and blood tests, before and after the weight loss intervention to see how their bodies change with weight loss.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Generally healthy men and women aged 18-70
- • BMI between 30-40
- • Less than 1 hour of exercise per week
- * Women:
- • 1. may be pre or post menopausal
- Exclusion Criteria:
- • Type 1 or Type 2 diabetes
- • Thyroid disease
- • History of lung disease
- • Active use of nicotine
- • Severe plasma lipid disorders
- • Taking hormone replacement drugs, blood thinners, or thiazoladinediones
- * Women:
- • 1. Currently going through menopause or peri-menopause
- • 2. Pregnant or breastfeeding
- • 3. History of Polycystic Ovary Syndrome
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported